January 2017 UrologyTimesJanuary2017.png
Studies reveal drop in PCa treatment, rise in metastatic diseaseFindings from two new studies provide insight on the impact of changing recommendations for prostate cancer screening and management.
Bone metastases Tx: 12-week dosing interval appears feasibleResults of a 2-year clinical trial support switching to a less frequent administration schedule when using zoledronic acid (Zometa) to prevent skeletal-related events in men with prostate cancer.
PCa: Emotional distress influences treatment decisionResearchers have found that the anxiety men often experience after being diagnosed with prostate cancer could lead to potentially unnecessary treatment options.
Laser-activated PCa therapy promising in phase III studyResearchers evaluate an experimental treatment called vascular-targeted photodynamic therapy in men with localized prostate cancer.
How I do it: Best urologic surgery articles of 2016In 2016, our "Hands On" section included articles about bulbomembranous urethroplasty, recurrent urinary tract infections, transgender surgery, and more.
Urolithiasis mortality rate high in lower income nationsResults of a study analyzing global trends in mortality attributable to urolithiasis show that the rate declined over a recent 20-year period.
Major decline in prostate Bx rates follows PSA publications“It is clear that in order to reduce the morbidity of PSA screening and early detection of prostate cancer, more needs to be done,” writes Badar M. Mian, MD.
Top 10 stone disease articles of 2016A comparison of dusting versus basketing, the question of whether shock wave lithotripsy should be retired, and an expert interview on difficult stones were among the most-read Urology Times articles on stone disease in 2016.